CML: Vaccine found to be of benefit

CML patients may become refractory to Gleevec. A recent study added a personalized immunotherapeutic cancer to their treatment program, AG-858. A positive response with this combination was noted. [P] Reference: Abstract #664, 39th Annual Meeting of ASCO.

Webmaster

September 22, 2003